OVID 8-K: SEC filing

Ovid Therapeutics

Filed with the SEC on Nov 10, 2026 · accession 0001628280-26-072494

OVID filed a 8-K (current report) with the SEC on Nov 10, 2026. A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

Summary of the filing

Ovid Therapeutics issued a press release announcing business updates and its third quarter 2026 financial results.

For details, click here →How to read a 8-K →

Key details

RegistrantOvid Therapeutics Inc.

Chief financial officerCharles Carter

✦ Ask GOAX AI about this filing — what it means for OVID, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for OVID?

Click here

Frequently asked questions

What did OVID file with the SEC on Nov 10, 2026?

OVID filed a 8-K (SEC filing). Ovid Therapeutics issued a press release announcing business updates and its third quarter 2026 financial results.

How do I read a 8-K?

A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

Other OVID SEC filings

Get alerts when OVID files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days

OVID overview OVID analysis OVID news Latest SEC filings